
ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

